Potential of chromatin modifying compounds for the treatment of Alzheimer's disease.

Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol Ther (2013) 0.90

Genomic integrity and the ageing brain. Nat Rev Neurosci (2015) 0.88

The potential of epigenetic therapies in neurodegenerative diseases. Front Genet (2014) 0.78

Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25

Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov (2006) 14.01

Alzheimer's disease is a synaptic failure. Science (2002) 13.82

Alzheimer's disease. N Engl J Med (2010) 13.13

HDAC6 is a microtubule-associated deacetylase. Nature (2002) 12.76

Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J (2003) 11.27

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer (2006) 10.73

Histone acetyltransferases. Annu Rev Biochem (2001) 10.00

The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet (2009) 9.68

Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer (2001) 9.12

Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun (2000) 9.09

Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays (1998) 7.79

Recent progress in the biology and physiology of sirtuins. Nature (2009) 7.73

The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 7.71

Physical performance measures in the clinical setting. J Am Geriatr Soc (2003) 7.67

Sirtuins in mammals: insights into their biological function. Biochem J (2007) 7.60

Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene (2007) 7.13

HDAC2 negatively regulates memory formation and synaptic plasticity. Nature (2009) 6.96

Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem (2001) 6.85

Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J (2001) 6.85

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol (2007) 6.16

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A (2003) 5.56

Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res (2007) 4.91

Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem (2009) 3.88

Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology (2009) 3.64

Retracted SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell (2010) 3.58

Histone acetylation: chromatin in action. Trends Biochem Sci (1997) 3.33

Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology (2001) 3.30

Control of cardiac growth by histone acetylation/deacetylation. Circ Res (2006) 3.25

Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron (2010) 3.15

Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci (2009) 2.95

The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J (2003) 2.81

Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation (2006) 2.70

Prospects: histone deacetylase inhibitors. J Cell Biochem (2005) 2.46

Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci (2007) 2.44

A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J Neurol Sci (1987) 2.43

Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med (2009) 2.39

Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med (2011) 2.36

Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors. J Biol Chem (2003) 2.35

Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem (2005) 2.31

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation. Proc Natl Acad Sci U S A (2008) 2.10

Resveratrol: a molecule whose time has come? And gone? Clin Biochem (1997) 1.96

Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs (2007) 1.95

Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression. Curr Opin Genet Dev (2003) 1.95

Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem (2005) 1.91

Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88

Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology (2009) 1.84

Resveratrol: its biologic targets and functional activity. Antioxid Redox Signal (2009) 1.81

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs (2010) 1.79

Neuroinflammatory processes in Alzheimer's disease. J Neural Transm (Vienna) (2010) 1.73

Chemical mechanisms of histone lysine and arginine modifications. Biochim Biophys Acta (2008) 1.69

Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med (2008) 1.68

The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci (2007) 1.68

Chronic divalproex sodium use and brain atrophy in Alzheimer disease. Neurology (2011) 1.66

Alzheimer disease. Dis Mon (2010) 1.64

HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One (2010) 1.63

Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci U S A (2010) 1.62

Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry (2004) 1.56

Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev (2002) 1.54

Trichostatin A attenuates airway inflammation in mouse asthma model. Clin Exp Allergy (2005) 1.53

Mechanisms of action of valproate: a commentatory. Neurochem Int (2000) 1.48

Resveratrol--a boon for treating Alzheimer's disease? Brain Res Rev (2006) 1.40

Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet (2005) 1.38

Histone deacetylase 6 interacts with the microtubule-associated protein tau. J Neurochem (2008) 1.38

Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets (2005) 1.38

The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. J Biol Chem (2010) 1.36

Neuroprotective effects of resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol (2004) 1.35

Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta (2010) 1.35

Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther (2010) 1.34

Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis (2009) 1.34

Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus (2010) 1.31

Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J (2009) 1.28

Tau--an inhibitor of deacetylase HDAC6 function. J Neurochem (2009) 1.27

The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations. Lancet Neurol (2011) 1.27

Protective effect of resveratrol on beta-amyloid-induced oxidative PC12 cell death. Free Radic Biol Med (2003) 1.25

The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal (2011) 1.24

Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J Am Geriatr Soc (2003) 1.22

Neuronal apoptosis induced by histone deacetylase inhibitors. Brain Res Mol Brain Res (1998) 1.22

Cardioprotective actions of grape polyphenols. Nutr Res (2008) 1.21

Romidepsin for the treatment of cutaneous T-cell lymphoma. Drugs Today (Barc) (2009) 1.19

Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis (2002) 1.18

Mammalian sirtuins and energy metabolism. Int J Biol Sci (2011) 1.17

Neuronal protection by sirtuins in Alzheimer's disease. J Neurochem (2005) 1.16

Neuroprotective properties of resveratrol and derivatives. Ann N Y Acad Sci (2011) 1.13

Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell (2011) 1.11

Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist (2002) 1.09

HDAC6 α-tubulin deacetylase: a potential therapeutic target in neurodegenerative diseases. J Neurol Sci (2011) 1.09

Sirtuins: molecular traffic lights in the crossroad of oxidative stress, chromatin remodeling, and transcription. J Biomed Biotechnol (2011) 1.03

Discovery of histone deacetylase 8 selective inhibitors. Bioorg Med Chem Lett (2011) 0.99

Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr Pharm Des (2009) 0.99

Identification and biology of α-secretase. J Neurochem (2011) 0.97

Biological and medicinal properties of grapes and their bioactive constituents: an update. J Med Food (2009) 0.95

Phenylbutyric acid rescues endoplasmic reticulum stress-induced suppression of APP proteolysis and prevents apoptosis in neuronal cells. PLoS One (2010) 0.93

Sodium 4-phenylbutyrate protects against spinal cord ischemia by inhibition of endoplasmic reticulum stress. J Vasc Surg (2010) 0.93

Trichostatin A abrogates airway constriction, but not inflammation, in murine and human asthma models. Am J Respir Cell Mol Biol (2012) 0.92

Dual roles of histone deacetylases in the control of cardiac growth. Novartis Found Symp (2004) 0.88

Large-scale separation of resveratrol, anthraglycoside A and anthraglycoside B from Polygonum cuspidatum Sieb. et Zucc by high-speed counter-current chromatography. J Chromatogr A (2001) 0.85

Phenylbutyric acid prevents rats from electroconvulsion-induced memory deficit with alterations of memory-related proteins and tau hyperphosphorylation. Neuroscience (2010) 0.81

Chromatin modifying agents - the cutting edge of anticancer therapy. Drug Discov Today (2011) 0.79

Alzheimer's disease and the glutamate NMDA receptor. Psychopharmacol Bull (2003) 0.79

Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep (2015) 1.10

Clonogenic assay: adherent cells. J Vis Exp (2011) 0.99

Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging (Albany NY) (2010) 0.90

The Warburg effect: molecular aspects and therapeutic possibilities. Mol Biol Rep (2015) 0.85

Utility of γH2AX as a molecular marker of DNA double-strand breaks in nuclear medicine: applications to radionuclide therapy employing auger electron-emitting isotopes. Curr Radiopharm (2011) 0.85

Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol Biol Rep (2015) 0.85

Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res (2011) 0.82

Histone deacetylase inhibition and dietary short-chain Fatty acids. ISRN Allergy (2011) 0.80

The early life origin theory in the development of cardiovascular disease and type 2 diabetes. Mol Biol Rep (2015) 0.80

Investigation of the biological properties of Cinnulin PF in the context of diabetes: mechanistic insights by genome-wide mRNA-Seq analysis. Pathobiol Aging Age Relat Dis (2012) 0.80

Trefoil factor-2 reverses airway remodeling changes in allergic airways disease. Am J Respir Cell Mol Biol (2012) 0.80

An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. Am J Transl Res (2012) 0.80

Protective effects of valproic acid against airway hyperresponsiveness and airway remodeling in a mouse model of allergic airways disease. Epigenetics (2011) 0.79

Influence of natural and synthetic histone deacetylase inhibitors on chromatin. Antioxid Redox Signal (2012) 0.79

Histone deacetylase inhibitors: can we consider potent anti-neoplastic agents for the treatment of asthma? Ann Clin Lab Sci (2012) 0.78

Cell cycle effects of L-sulforaphane, a major antioxidant from cruciferous vegetables: The role of the anaphase promoting complex. Hell J Nucl Med (2014) 0.77

Lactate as an insidious metabolite due to the Warburg effect. Mol Biol Rep (2015) 0.77

Mechanisms of action of phenolic compounds in olive. J Diet Suppl (2012) 0.77

RNA sequencing supports distinct reactive oxygen species-mediated pathways of apoptosis by high and low size mass fractions of Bay leaf (Lauris nobilis) in HT-29 cells. Food Funct (2015) 0.76

Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair. J Photochem Photobiol B (2011) 0.76

Biological effects of the olive polyphenol, hydroxytyrosol: An extra view from genome-wide transcriptome analysis. Hell J Nucl Med (2014) 0.76

Safety and efficacy of pralatrexate in the management of relapsed or refractory peripheral T-cell lymphoma. Clin Med Insights Oncol (2012) 0.75